ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDsJune 1, 2023RheumatologyPulmonology
Multiple successive biologic to biosimilar switches deemed safe and effectiveMay 31, 2023GastroenterologyRheumatologyMixed Topics
AxSpA remission on TNFi seen in half of patients with comorbid IBDMay 25, 2023GastroenterologyRheumatology
FDA approves Yuflyma as ninth adalimumab biosimilarMay 24, 2023Rare DiseasesDermatologyGastroenterologyRheumatology
FDA approves autoinjector pen for Humira biosimilar, CyltezoMay 24, 2023DermatologyGastroenterologyRheumatologyRare Diseases
Biomarkers for measuring lupus nephritis treatment response gain groundMay 19, 2023NephrologyRheumatology
